

## NAMS POSITION STATEMENT

# The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society

---

### Abstract

**Objective:** To update and expand the 2013 position statement of The North American Menopause Society (NAMS) on the management of the genitourinary syndrome of menopause (GSM), of which symptomatic vulvovaginal atrophy (VVA) is a component.

**Methods:** A Panel of acknowledged experts in the field of genitourinary health reviewed the literature to evaluate new evidence on vaginal hormone therapies as well as on other management options available or in development for GSM. A search of PubMed was conducted identifying medical literature on VVA and GSM published since the 2013 position statement on the role of pharmacologic and nonpharmacologic treatments for VVA in postmenopausal women. The Panel revised and added recommendations on the basis of current evidence. The Panel's conclusions and recommendations were reviewed and approved by the NAMS Board of Trustees.

**Results:** Genitourinary syndrome of menopause affects approximately 27% to 84% of postmenopausal women and can significantly impair health, sexual function, and quality of life. Genitourinary syndrome of menopause is likely underdiagnosed and undertreated. In most cases, symptoms can be effectively managed. A number of over-the-counter and government-approved prescription therapies available in the United States and Canada demonstrate effectiveness, depending on the severity of symptoms. These include vaginal lubricants and moisturizers, vaginal estrogens and dehydroepiandrosterone (DHEA), systemic hormone therapy, and the estrogen agonist/antagonist ospemifene. Long-term studies on the endometrial safety of vaginal estrogen, vaginal DHEA, and ospemifene are lacking. There are insufficient placebo-controlled trials of energy-based therapies, including laser, to draw conclusions on efficacy and safety or to make treatment recommendations.

**Conclusions:** Clinicians can resolve many distressing genitourinary symptoms and improve sexual health and the quality of life of postmenopausal women by educating women about, diagnosing, and appropriately managing GSM. Choice of therapy depends on the severity of symptoms, the effectiveness and safety of treatments for the individual patient, and patient preference. Nonhormone therapies available without a prescription provide sufficient relief for most women with mild symptoms. Low-dose vaginal estrogens, vaginal DHEA, systemic estrogen therapy, and ospemifene are effective treatments for moderate to severe GSM. When low-dose vaginal estrogen or DHEA or ospemifene is administered, a progestogen is not indicated; however, endometrial safety has not been studied in clinical trials beyond 1 year. There are insufficient data at present to confirm the safety of vaginal estrogen or DHEA or ospemifene in women with breast cancer; management of GSM should consider the woman's needs and the recommendations of her oncologist.

**Key Words:** Dyspareunia – Genitourinary syndrome of menopause – Ospemifene – Vaginal dehydroepiandrosterone – Vaginal dryness – Vaginal estrogen – Vulvovaginal atrophy.

---

**G**enitourinary syndrome of menopause (GSM) describes the symptoms and signs resulting from the effect of estrogen deficiency on the female

genitourinary tract. Symptoms associated with GSM are highly prevalent, affecting approximately 27% to 84% of postmenopausal women.<sup>1-4</sup> In one report of more than

---

Received May 14, 2020; revised and accepted May 14, 2020.

This position statement was developed by The North American Menopause Society (NAMS) consisting of representatives of the NAMS Board of Trustees and other experts in women's health: Stephanie S. Faubion, MD, MBA, FACP, NCMP, IF; Sheryl A. Kingsberg, PhD; Jan L. Shifren, MD, NCMP, FACOG; Caroline Mitchell, MD, MPH; Andrew M. Kaunitz, MD, FACOG, NCMP; Lisa Larkin, MD, FACP, NCMP, IF; Susan Kellogg Spadt, PhD, CRNP, IF, FCST, CSC; Amanda Clark, MD, MCR, NCMP, FACOG; James A. Simon, MD, CCD, NCMP, IF, FACOG. The

Board of Trustees conducted independent review and revision and approved the position statement on May 5, 2020.

This position statement was made possible by donations to the NAMS Education & Research Fund. 🌱 There was no commercial support.

Address correspondence to: The North American Menopause Society, 30100 Chagrin Blvd, Suite 201, Pepper Pike, OH 44124. E-mail: info@menopause.org. Website: www.menopause.org.

900 women undergoing routine examinations, GSM was identified in 84% of women 6 years after menopause.<sup>4</sup> Principal symptoms included vaginal dryness, painful sex, burning, and dysuria. In contrast to vasomotor symptoms (VMS) that usually improve over time, GSM is generally progressive without effective therapy. Despite the high prevalence of GSM and lack of improvement without treatment, only a minority of affected women seek help or are offered treatment by their healthcare providers.<sup>5,6</sup>

In a survey of 1,858 US postmenopausal women with genitourinary symptoms, 50% had never used any therapy for this problem.<sup>6</sup> The reluctance of women as well as healthcare providers to initiate discussion of genitourinary symptoms and safety concerns about hormone therapies contribute to limited assessment and treatment of GSM.<sup>7,8</sup>

The genitourinary syndrome of menopause often has significant adverse effects on a woman's sexual health and quality of life (QOL).<sup>9</sup> Women who are not sexually active also experience bothersome symptoms of GSM, affecting activities of daily living.<sup>10</sup> In the *Vaginal Health: Insights, Views & Attitudes* (VIVA) online survey of 3,520 postmenopausal women in six countries, 45% reported experiencing vaginal symptoms, and 75% felt that their symptoms negatively affected their lives.<sup>11</sup> In 500 US women in the VIVA survey, of the 48% with vaginal discomfort, the most common symptoms were vaginal dryness and pain during intercourse.<sup>5</sup> Women in VIVA in the United States reported these adverse events (AEs) of vaginal discomfort:

- Negative effect on their lives (80%)
- Adverse effects on sexual intimacy (75%)
- Feeling less sexual (68%)
- Feeling old (36%)
- Negative consequences on marriage/relationship (33%)
- Negative effect on self-esteem (26%)
- Lower QOL (25%)

In a survey of 3,046 US women, *Real Women's Views of Treatment Options for Menopausal Vaginal Changes* (REVIVE),<sup>7</sup> women reported that their vulvovaginal atrophy (VVA) symptoms:

- Led to some loss of intimacy (85%)
- Detracted from enjoyment of sex (59%)
- Interfered with their relationship (47%)
- Negatively affected sleep (29%)
- Adversely affected general enjoyment of life (27%)

This updated position statement reviews the science of genitourinary aging and assesses the safety and effectiveness of available treatment options for postmenopausal women with GSM.

## METHODS

A nine-member Panel composed of expert clinicians and researchers in the field of genitourinary health reviewed the literature to evaluate new evidence on management strategies, including vaginal estrogens, vaginal dehydroepiandrosterone

(DHEA), ospemifene, and other management options available or in development for symptomatic GSM. A literature search was conducted using the terms “genitourinary syndrome of menopause/GSM,” “vulvovaginal atrophy/VVA,” “atrophic vaginitis,” “dyspareunia,” “vaginal dryness,” and “vaginal lubrication.” If evidence was contradictory or inadequate to form a conclusion, a consensus-based opinion was established.

The Panel's completed draft of the updated Position Statement was submitted to the NAMS Board of Trustees for additional review, comments, and edits. The Board is composed of both clinicians and researchers from multiple specialties and disciplines. The Board approved the Position Statement with edits after final Panel review.

## TERMINOLOGY

*Genitourinary syndrome of menopause* describes the symptoms and signs resulting from the effect of estrogen deficiency on the female genitourinary tract, including the vagina, labia, urethra, and bladder.<sup>12</sup> This syndrome includes genital symptoms of dryness, burning, and irritation; urinary symptoms and conditions of dysuria, urgency, and recurrent urinary tract infections (UTIs); and sexual symptoms of pain and dryness. Physical changes and signs are varied. Women may experience some or all of the symptoms and signs, which must be bothersome for a diagnosis of the syndrome. Other causes of similar signs and symptoms must be ruled out, including vulvovaginal dermatoses, infection, or cancer.

*Vulvovaginal atrophy* is a component of GSM.<sup>13</sup> Although VVA was the commonly used term in the past to describe the genitourinary changes of menopause, it has limitations. Vulvovaginal atrophy describes the appearance of the genital tissues but not the associated symptoms. It does not include urinary tract changes related to estrogen deficiency, and the term *atrophy* has negative associations for women. The term genitourinary syndrome of menopause was developed during a consensus conference of experts<sup>12</sup> and subsequently was accepted as the preferred term by many medical societies, including The North American Menopause Society and the American College of Obstetricians and Gynecologists.

## ANATOMY AND PHYSIOLOGY

The genital and lower urinary tract share a common embryologic origin in women, with the urethra, bladder trigone, vulvar vestibule, and the upper vagina all derived from the same estrogen receptor (ER)-rich primitive urogenital sinus tissue.<sup>14</sup> The vulva is also derived from the urogenital sinus, but the epithelium of the labia majora is of ectodermal origin. The vagina is composed of an inner stratified squamous epithelium, a middle muscular layer, and an outer fibrous layer. In the presence of endogenous estrogen after puberty and before menopause, the lining of the vagina is characterized by a thickened, rugated surface that is well vascularized and lubricated in most women.

Estrogen is a dominant regulator of vaginal and lower urinary tract physiology. Estrogen receptor- $\alpha$  is present in

the vaginal tissues of both premenopausal and postmenopausal women, whereas ER- $\beta$  appears to have no or low expression in postmenopausal vaginal tissue. Estrogen therapy (ET) does not appear to affect the presence of ER- $\beta$ .<sup>15,16</sup> Estrogen receptor density is highest in the vagina, with decreasing density across the external genitalia to the skin. The density of the androgen receptor is the reverse. There are low levels in the vagina and higher levels in the external genitalia. Progesterone receptors are found in the vagina and the transitional epithelium of the vulvovaginal junction.<sup>17</sup>

Estrogen receptors have also been found on autonomic and sensory neurons in the vagina and vulva. Estrogen therapy has been reported to decrease the density of sensory nociceptor neurons in the vagina. This function may serve to decrease the discomfort associated with GSM.<sup>18</sup> With respect to the lower urinary tract, estrogen and progesterone receptors have been identified in the urethra, bladder, and pelvic floor muscles.<sup>14</sup>

The changing physiology of the vaginal epithelium after menopause is not completely understood. On the basis of a cell-culture model that used vaginal-cervical epithelial cells, diminished estrogen levels and aging were found to be independent factors in decreasing vaginal-cervical paracellular permeability, a change potentially related to vaginal dryness.<sup>19</sup> With atrophy, wet-mount microscopy shows more than one white blood cell per epithelial cell and immature vaginal epithelial cells with relatively large nuclei (parabasal cells). Cytology shows an increase in parabasal and intermediate cells, and superficial cells decrease or are absent.<sup>20</sup> Immune cell populations seem to be similar or slightly decreased in number, with similar cytolytic capacity as before menopause.<sup>21-23</sup> However, some studies show differences in inflammatory markers in the vaginal fluid of postmenopausal women compared with premenopausal women.<sup>24</sup>

Hormone changes throughout the life cycle influence the vaginal microbiome from birth through postmenopause.<sup>25,26</sup> During the reproductive years, the presence of a microbial community dominated by *Lactobacillus* species is associated with a lower pH and lower risk for bacterial vaginosis (BV), sexually transmitted infections, UTIs, and HIV infection.<sup>27-35</sup>

After menopause, women are less likely to have a *Lactobacillus*-dominant vaginal bacterial community and less likely to have a low vaginal pH.<sup>26,36,37</sup> Although cultivation-based studies show a significantly lower quantity of vaginal *Lactobacillus* in postmenopausal women,<sup>37</sup> several newer sequencing studies observe that close to half have a high proportion of lactobacilli.<sup>38,39</sup> In one study, a higher proportion of *Lactobacillus* correlated inversely with examiner-reported dryness in postmenopausal women,<sup>38</sup> but in another study, there was no association between *Lactobacillus* dominance and the severity of patient-reported symptoms.<sup>40</sup>

The vaginal bacteria community of postmenopausal women has many similarities with that of reproductive-aged women with BV: high pH,<sup>36</sup> higher diversity,<sup>41</sup> and an abnormal Nugent score.<sup>42</sup> In many women with GSM, however, these abnormalities reflect a decline in lactobacilli rather than an

increase in the prevalence of pathogens.<sup>42,43</sup> Treatment with systemic or topical estrogen is associated with an increase in detection of vaginal lactobacilli.<sup>44,45</sup> This suggests that for many postmenopausal women, the best approach to promoting a healthy vaginal microbial community is not antibiotic therapy (as though treating BV) but rather vaginal estrogen therapy.

## PRESENTATION

The diagnosis of GSM requires the presence of both characteristic examination findings and bothersome symptoms. The most commonly reported symptoms include irritation of the vulva, inadequate vaginal lubrication, burning, dysuria, dyspareunia, and vaginal discharge. Symptoms adversely affecting sexual function are often the most distressing.<sup>12,46,47</sup>

Signs of GSM include labial atrophy, vaginal dryness, introital stenosis, clitoral atrophy, and phimosis of the prepuce. Severe GSM can result in a vaginal surface that is friable and hypopigmented, with petechiae, ulcerations, and tears, as well as urethral findings such as caruncles, prolapse, or polyps. Bleeding may occur from minimal trauma, such as speculum insertion. Genitourinary atrophic changes increase the likelihood of trauma, pain, recurrent UTIs, bleeding with or after sex, and absence of sexual activity.<sup>20,47</sup>

The genitourinary syndrome of menopause most commonly develops in the setting of hypoestrogenism associated with natural menopause. Hypoestrogenic states also may occur in the setting of primary ovarian insufficiency (POI), surgical menopause (bilateral oophorectomy with or without hysterectomy), hypothalamic amenorrhea, the postpartum state and breastfeeding, use of gonadotropin-releasing hormone agonists or aromatase inhibitors (AIs), and cancer treatments such as surgery, pelvic radiation therapy, or chemotherapy that render ovaries inactive, either temporarily or permanently.

Several studies suggest that early estrogen deficiency caused by premature menopause or POI is associated with more severe sexual dysfunction compared with age-matched controls.<sup>48,49</sup> Younger women with vaginal atrophy and dyspareunia may be especially distressed by changes in sexual function.

Women with surgical menopause often present with a more severe GSM symptom profile than do women with natural menopause, likely because of the concomitant, abrupt, and persistent 50% decline in circulating androgen levels that occurs in addition to the loss of estradiol.<sup>50,51</sup> Genitourinary syndrome of menopause that develops in the setting of chemotherapy-induced menopause has been associated in some studies with greater sexual dysfunction and distress<sup>52-54</sup> and with poorer QOL outcomes.<sup>55-58</sup> Younger women with GSM related to induced menopause from cancer treatment may be especially distressed by changes in sexual function.<sup>52,55</sup> The stress, fatigue, and mood changes that accompany a cancer diagnosis and its treatment also contribute to sexual problems.

Aromatase inhibitors reduce breast cancer recurrence by blocking conversion of androgens to estrogens and

inducing a profound estrogen-deficiency state. The magnitude and duration of estrogen deficiency induced by AIs result in the development of severe GSM in most survivors, particularly given that extended duration therapy is now typical.<sup>59-61</sup> Compared with tamoxifen, AIs result in a greater incidence of vaginal dryness and dyspareunia, causing a large percentage of AI users to express dissatisfaction with their sex lives.<sup>60,62-64</sup>

## EVALUATION AND DIAGNOSIS

The evaluation of GSM includes a history and pelvic examination. A medical history may identify contributing factors, alternative etiologies, and effective therapeutic interventions. The pelvic examination should identify signs consistent with GSM and eliminate other pathologic conditions that may cause similar symptoms.

### History

Because women may not spontaneously report symptoms of GSM and related sexual concerns, providers should inquire about symptoms in all perimenopausal and postmenopausal women as part of a routine review of systems. The EMPOWER survey queried 1,858 menopausal US women with symptoms suggestive of GSM and found that in women who had never used any treatment, almost three-quarters had never discussed their symptoms with a healthcare provider.<sup>6</sup> The main reason for this reticence was the assumption that GSM was simply a natural part of aging with which women needed to live. Results of the *Women's Voices in the Menopause* survey revealed that in more than 1,000 US respondents, one-third of those with vaginal discomfort had not spoken with anyone regarding their condition and one-third preferred that discussion regarding vaginal discomfort be initiated by their healthcare providers.<sup>65</sup>

These survey results underscore the importance of clinicians being proactive in asking menopausal women whether symptoms suggestive of GSM are present. The goal of the history is to determine whether symptoms of GSM are present, whether they are bothersome, and how they affect the woman's sexual health and QOL. In the absence of symptoms, atrophic changes noted on examination do not necessarily require treatment, although women should be informed that these changes may worsen over time without proactive management.

Symptoms similar to GSM result from many other conditions. The differential diagnosis includes allergic or inflammatory conditions (eg, lichen sclerosus, erosive lichen planus, desquamative inflammatory vaginitis, contact dermatitis, and cicatricial pemphigoid), vulvovaginal candidiasis and other infections, trauma, foreign bodies, malignancy, vulvodynia, vestibulodynia, chronic pelvic pain, provoked pelvic floor hypertonia (previously known as vaginismus), and other medical conditions (eg, diabetes, lupus erythematosus) or psychological disorders. An alternate etiology is more likely in women with chronic or

recurrent vulvovaginal symptoms that were present before menopause.

Documentation of GSM should include a description of symptoms, including time of onset, duration, level of associated distress, and effect on QOL. A sexual history that includes partner relationship(s), current level and types of sexual activity, and the effect of GSM symptoms on sex life and partner relationships is useful in determining management strategies. Previous interventions should be discussed, including their efficacy and adverse effects.

For a woman with a history of cancer, additional information is relevant, including cancer site, age at diagnosis, hormone receptor status, treatments (past, current), and type of menopause (spontaneous or induced). Cancer treatments, especially surgery and radiation therapy, can damage the vaginal epithelium, the vascular supply, and the anatomy of the vaginal canal. Some treated women experience a narrowed or foreshortened vagina. Genitourinary changes associated with cancer treatments can produce pain with pelvic examinations, dyspareunia, recurrent UTIs, and an increased risk of vaginal infections.<sup>52,66</sup>

### Physical examination

The pelvic examination helps to exclude other vulvovaginal conditions that can cause similar symptoms. As GSM progresses, examination of the external genitalia often reveals reduced mons pubis and labia majora bulk, reduced labia minora tissue and pigmentation, and prominence (telescoping) and erythema of the urethral meatus. Urethral caruncle, a benign outgrowth of inflammatory tissue arising from the posterior urethral meatus, is common in postmenopausal women and likely related to hypoestrogenism. The clitoris may recede and in some cases become completely flush with the surrounding tissue. The vestibular tissue may become pale.

If the introitus is noted to be narrow, use of a narrow pediatric vaginal speculum with lubricant is appropriate. The vaginal mucosa may appear smooth (loss of rugation), shiny, and dry. Minimal blunt trauma from the speculum may result in petechiae (reflecting mucosal thinning) or bleeding (friability). With progression of GSM, attenuation of the vaginal fornices may be apparent, and the cervix may appear flush with the vaginal apex.

With atrophic vaginitis, brown or yellow (sometimes malodorous) discharge may be present. With severe GSM, there may be such shortening of the vaginal vault and narrowing of the introitus that speculum insertion and visual inspection of the vaginal vault as well as cervix may not be possible.

Although the vaginal maturation index (VMI) and vaginal pH are routinely assessed in clinical trials, they are not essential to make a diagnosis of GSM in clinical practice. With GSM, vaginal pH is typically greater than 5.0. Wet-mount microscopy shows more than one white blood cell per epithelial cell, immature vaginal epithelial cells with relatively large nuclei (parabasal cells), and reduced or absent lactobacilli. Repopulation with diverse flora can occur,



including enteric organisms commonly associated with UTIs.<sup>67</sup> The appearance of the wet mount in severe GSM may be difficult to distinguish from that of desquamative inflammatory vaginitis or vaginal erosive lichen planus.<sup>68</sup> A culture or vulvovaginal biopsy should be considered if there are atypical findings or if the vulvovaginal symptoms fail to resolve after a trial of vaginal estrogens or DHEA.

A woman's symptoms do not always correlate with physical findings. For example, a woman who is not sexually active may have few symptoms, despite signs of advanced genitourinary atrophy on examination. In contrast, a woman with an active sex life may complain of dryness and discomfort with sex, whereas the pelvic examination suggests only mild atrophy. Of note, women who are not sexually active also may be bothered by symptoms related to GSM, including discomfort with exercise or dysuria and benefit from treatment. Thus, both history and examination are essential to making a correct diagnosis.

### TREATMENT

The primary goal of treating GSM is to alleviate symptoms. For the woman with GSM, after excluding other causes of her symptoms, treatment can be approached in a stepwise fashion based on symptom severity. First-line therapies for less-severe symptoms include nonhormone vulvar and vaginal lubricants with sexual activity and long-acting vaginal moisturizers used regularly (several times/wk). Although not supported by clinical trials, regular, gentle vaginal stretching exercises (eg, pain-free insertion of a finger or dilator) or sexual activity may reduce GSM symptoms. Prescription therapies include low-dose vaginal estrogens, vaginal DHEA inserts, and oral ospemifene. For women with moderate to severe dyspareunia associated with GSM with concurrent VMS, transdermal and oral HT are effective options. Symptom reduction may take 1 to 3 months, and continued therapy is generally required because symptoms are likely to recur on cessation of treatment. Outcomes data on the symptom recurrence rate are lacking.

Some women may already have vaginal narrowing or provoked pelvic floor hypertonia limiting vaginal penetration. Gentle stretching of the vagina with the use of lubricated vaginal dilators of graduated sizes (or an expandable dilator) can play an important role in restoring and maintaining vaginal function for penetration. Reinitiating regular sexual activity once vaginal penetration is again comfortable, if desired, may help to maintain vaginal pliability. Many women with this condition benefit from referral for pelvic floor physical therapy (PFPT).<sup>69,70</sup> Starting pharmacologic treatment to restore tissue integrity before initiating vaginal dilatation and/or PFPT may facilitate progress.

### Nonprescription therapies

#### Lubricants and moisturizers

First-line therapies to alleviate symptoms of GSM include over-the-counter (OTC) nonhormone vaginal lubricants and moisturizers, a number of which are available (Table 1), but

**TABLE 1.** Examples of nonhormone therapeutic options for dyspareunia secondary to GSM

Lubricants	Moisturizers
<i>Water based</i>	
Astroglide Liquid	Replens
Astroglide Gel Liquid	Me Again
Astroglide	Feminease
Good Clean Love	K-Y SILK-E
Just Like Me	Luvena
K-Y Jelly	Revaree
Pre-Seed	Silken Secret
Slippery Stuff	Hyalogyn
Liquid Silk	
YES WB	
SYLK	
Sliquid	
<i>Silicone based</i>	
Astroglide X	
ID Millennium	
K-Y Intrigue	
Pink	
Pjur Eros	
Uberlube	
Sliquid	
<i>Oil based</i>	
Elégance Women's Lubricants	
Olive oil	
YES OB	

few clinical studies have been conducted on the efficacy of these products.

A vaginal moisturizer is a bioadhesive product used regularly, most often two to three times a week, irrespective of the timing of sexual activity. The goal of use is to reduce daily symptoms of GSM as well as to facilitate comfortable sexual activity. Data suggesting improvement in genitourinary symptoms with nonhormone treatments are sparse, and to date, there are no adequately powered, randomized, double-blind, placebo controlled studies directly comparing low-dose vaginal estrogen therapies or vaginal DHEA with commonly used nonhormone treatments. One randomized, controlled, but short-term study demonstrated effectiveness of a pH-balanced gel compared with placebo in women treated for breast cancer. Mild irritation with administration was noted.<sup>71</sup> In a randomized, controlled trial (RCT; N = 302), a significant improvement in most bothersome symptom severity was seen in all three arms: the vaginal estradiol tablet (plus placebo gel), vaginal moisturizer (plus placebo tablet), and dual placebo arms.<sup>72</sup> In that trial, the placebo gel likely had lubricating properties.

Vaginal lubricants are used by both (or all) partners to decrease discomfort caused by friction during sex. Regular use has also been associated with increase in pleasure and ease of orgasm.<sup>73</sup> In a review and meta-analysis, the effect of lubricant use on symptom severity could not be compared in studies because of heterogeneity. However, the meta-analysis of sexual function outcomes showed a small advantage to hormone-based therapies over lubricants in restoring sexual function.<sup>74</sup> One small crossover study in survivors of breast cancer demonstrated greater benefit with silicone-based lubricants compared with water based.<sup>75</sup>

In studies examining the safety of personal moisturizers and lubricants, investigators found that a number of water-based products are hyperosmolar.<sup>76,77</sup> This characteristic is associated with epithelial cellular toxicity and damage in cultures of epithelial cells and ectocervical explants. Near iso-osmolar and silicone-based lubricants did not have this effect. The World Health Organization recommends an osmolarity of less than 1,200 mOsm/kg.<sup>78</sup> One jelly and one moisturizer also were found to be toxic to lactobacilli. There are very few data on the health and safety effects of lubricants that contain flavors (sugar), warming properties, or solvents and preservatives such as propylene glycol and parabens. One study on the use of vaginal products in women aged 18 to 65 years reported a 2.2-fold risk of BV in women using petroleum jelly compared with controls and increased colonization with candida species with users of oils compared with nonusers.<sup>79</sup>

Because there are no published reports on the irritation potential of OTC vaginal lubricants and moisturizers, women can test these on a small patch of skin for 24 hours before using them intravaginally. If the product they test successfully on the skin still causes irritation in the vagina, a woman can switch to an iso-osmolar, propylene glycol-free, or silicone-based product (Table 1). It is noteworthy that oil-based lubricants can erode condoms; however, most brands of water-based and silicone-based lubricants are latex safe and condom compatible.

### *Hyaluronic acid*

Hyaluronic acid is a polymer found in cartilage and other soft tissues in the body that is added to many commercial skin-care and wound-healing products because of its purported effect of drawing moisture to any area to which it is applied. In four small RCTs comparing hyaluronic acid to placebo or vaginal ET, the former was associated with a similar decrease in severity of dryness and dyspareunia.<sup>80-83</sup> To date, there is no evidence that products with hyaluronic acid have a greater benefit than nonhyaluronic acid lubricants or moisturizers.

### *Herbal products*

Herbal products appear ineffective for GSM. The Herbal Alternatives for Menopause study, a double-blind RCT in 351 women, identified no change in vaginal dryness, vaginal cytology, follicle-stimulating hormone or estradiol levels following treatment for 1 year with black cohosh, a multi-botanical supplement, or soy.<sup>84</sup>

### **Prescription therapies**

For women with persistent GSM symptoms after nonhormone interventions, prescription therapies may provide greater benefit.

### *Vaginal estrogen*

Estrogen delivered vaginally provides sufficient estrogen to relieve genitourinary symptoms with minimal absorption and is preferred over systemic therapy when only genitourinary

symptoms are present.<sup>85,86</sup> When systemic HT is needed to treat other menopause symptoms, a woman also will generally derive satisfactory resolution of her genitourinary symptoms, although additional low-dose vaginal estrogen may be added if needed.

Efficacy studies of low-dose vaginal ET use both subjective and objective outcome measures. Subjective effects are often assessed using patient-reported outcome measures that include improvements in symptoms such as dyspareunia, vaginal dryness, and lower urinary tract symptoms and clinician-reported outcomes such as the appearance of the vulvo-vaginal tissues. Objective outcomes include decreases in vaginal pH, increases in the number of vaginal lactobacilli, and favorable shifts in the vaginal and/or urethral cytology (greater numbers and percentages of superficial cells and fewer numbers and percentages of parabasal cells).<sup>87,88</sup>

### *Efficacy*

Low-dose vaginal ET is available in several forms, including cream (estradiol, estrone, and conjugated estrogens), a slow-release estradiol intravaginal ring, and an estradiol vaginal tablet and insert. Products vary in dosage and formulation (Table 2).<sup>89-97</sup> All approved products have proven efficacy in placebo-controlled RCTs.<sup>86,98-111</sup> In the United States, FDA requires efficacy data for treatment of a specific, most bothersome symptom, which includes dyspareunia, vaginal dryness, vaginal/vulvar irritation, vaginal soreness, dysuria, or bleeding associated with sexual activity. Dyspareunia and vaginal dryness are the most common indications for low-dose vaginal ET.

The comparative efficacy of the various forms of vaginal ET was evaluated in a 2016 Cochrane review comparing 19 trials.<sup>112</sup> This review concluded that all tested products alleviated symptoms of vaginal dryness and dyspareunia with similar efficacy. Comparative analyses of these trials are limited by variations in methods and outcome measures, small sample sizes, lack of blinding, and substantial heterogeneity of results. Some trials of the same estrogen preparation used different doses or dosing schedules. Some trials included preparations not approved for use in the United States or in Canada.

### *Vaginal estrogen and urinary symptoms*

In a 2014 systematic review that included 44 RCTs, assessment of urinary symptoms was variable, leading to a lower quality of evidence for the effectiveness of vaginal estrogen for urinary symptoms compared with vulvovaginal symptoms.<sup>113</sup> This review reported moderate-quality evidence supporting vaginal ET in the treatment of urge incontinence and recurrent UTIs and low or very-low quality evidence supporting the use of vaginal ET for improvement of dysuria, urinary frequency and urgency, nocturia, and stress incontinence.

A Cochrane review of vaginal ET for urinary incontinence determined that vaginal ET improves incontinence (relative risk [RR], 0.74; 95% confidence interval [CI], 0.64-0.86) but

**TABLE 2.** Government-approved therapies for genitourinary syndrome of menopause in the United States and Canada

Type	Composition	Product name	Commonly used starting dose	Commonly used maintenance dose	Typical serum estradiol level (pg/mL)
Vaginal creams	17B-estradiol 0.01% (0.1 mg active ingredient/g)	Estrace vaginal cream <sup>a</sup>	0.5-1 g/d for 2 wk	0.5-1 g 1-3 times/wk	Variable
	Conjugated estrogens (0.625 mg active ingredient/g)	Premarin vaginal cream	0.5-1 g/d for 2 wk	0.5-1 g 1-3 times/wk	Variable
	Estrone 0.1% (1 mg active ingredient/g)	Estragyn vaginal cream <sup>b</sup>		0.5-4 g/d, intended for short-term use; progestogen recommended	Variable
Vaginal inserts	17B estradiol inserts	Imvexxy <sup>a</sup>	4 or 10 µg/d for 2 wk	1 insert twice/wk	3.6 (4 µg) 4.6 (10 µg)
	Estradiol hemihydrate tablets	Vagifem Yuvafem	10 µg/d for 2 wk	1 tablet twice/wk	5.5
	Prasterone (DHEA) inserts	Intrarosa	6.5 mg/d	1 insert/d	5
Vaginal ring	17β estradiol	Estring	2 mg ring releases approx 7.5 µg/d	Replace ring every 90 days	8
Oral tablet	Ospemifene	Osphena <sup>a</sup>	60 mg/d	1 tablet by mouth/d	N/A

DHEA, dehydroepiandrosterone.

Products not marked are available in both the United States and Canada.

<sup>a</sup>Available in the United States but not Canada.

<sup>b</sup>Available in Canada but not the United States.

Estrace<sup>89</sup>; Premarin<sup>90</sup>; Estragyn<sup>91</sup>; Imvexxy<sup>92</sup>; Vagifem<sup>93</sup>; Yuvafem<sup>94</sup>; Intrarosa<sup>95</sup>; Estring<sup>96</sup>; Osphena.<sup>97</sup>

that systemic estrogen alone and in combination with a progestogen worsens incontinence (RR, 1.32; 95% CI, 1.17-1.48 and RR, 1.11; 95% CI, 1.04-1.18, respectively).<sup>114</sup> Most of these studies were conducted for reasons other than urinary symptoms, failed to use validated tools to assess symptom severity and QOL, and showed statistically significant but not clinically relevant changes. For example, in the Heart and Estrogen/Progestin Replacement Study, women randomized to systemic oral estrogen plus progestogen therapy experienced 0.7 more leak episodes per week compared with 0.1 fewer episodes in the placebo group, but both changes met the a priori definition of “no change in incontinence severity.”<sup>115</sup>

Few trials have been conducted comparing vaginal ET to other treatments for postmenopausal urinary tract symptoms. Two small trials comparing vaginal ET (conjugated equine estrogens) to pelvic floor muscle therapy (PFMT) for urinary incontinence favored PFMT over vaginal estrogen,<sup>114</sup> but a trial that compared estradiol alone to estradiol combined with pelvic floor rehabilitation favored combined therapy.<sup>69</sup> A comparison of the estradiol ring to oral oxybutynin showed similar efficacy for treatment of overactive bladder but with different AEs; oxybutynin resulted in more dry mouth, constipation, and blurry vision, whereas the estradiol ring resulted in more vaginal discharge.<sup>116</sup> When women present with both vulvovaginal and urinary symptoms, an initial trial of vaginal ET is prudent. If urinary symptoms are not sufficiently improved or resolved after 3 months of vaginal ET, the use of other evidence-based therapies for urinary tract symptoms is warranted.<sup>117</sup>

Recurrent UTI, defined as the occurrence of two culture-proven UTIs in 6 months or three culture-proven UTIs in 1 year, commonly affects postmenopausal women and is a component of GSM.<sup>118</sup> Treatment of GSM with vaginal ET

(conjugated equine estrogen cream or low-dose estradiol vaginal ring) in a small RCT reduced the frequency of recurrent UTIs in postmenopausal women.<sup>119</sup> An RCT of vaginal estradiol cream (0.5 mg) in postmenopausal women with recurrent UTIs led to a significant decrease in number of UTI episodes per year (0.5 compared with 5.9).<sup>120</sup> In another randomized trial, the low-dose estradiol ring was found to prolong the time to next recurrence in postmenopausal women with recurrent UTIs and to decrease the number of recurrences per year (RR, 0.64).<sup>121</sup>

Women who use a vaginal pessary for treatment of utero-vaginal prolapse are often advised to use vaginal ET to facilitate pessary use and to limit potential complications such as vaginal discharge and vaginal wall erosions. Prospective data are lacking, but observational studies show lower discontinuation rates and less vaginal discharge when pessary users are treated with vaginal ET.<sup>122</sup>

### Safety

Low-dose vaginal ET has a more favorable risk profile than systemic ET because estrogen doses are significantly lower (Table 2).<sup>89-97</sup> Estrogens are systemically absorbed from the vagina in a dose-dependent manner, and in general, serum estrogen levels reported with use of low-dose vaginal ET remain within the postmenopause range.<sup>123</sup> A review of systemic estradiol measurements reported baseline levels in normal, untreated postmenopausal women of 3.1 pg/mL to 4.9 pg/mL using highly sensitive assays such as liquid or gas chromatography/mass spectroscopy and levels that were undetectable to 10.5 pg/mL using the less-sensitive radioimmunoassay.<sup>85</sup> Serum estradiol levels with use of the low-dose vaginal ring (releasing approximately 7.5 µg/d) ranged from 5 pg/mL to 10 pg/mL.<sup>107,124,125</sup> Serum estradiol levels with use of the 10-µg vaginal tablet ranged from 3 pg/mL

to 11 pg/mL.<sup>126-128</sup> Serum estradiol levels after daily use of the 4- $\mu$ g and 10- $\mu$ g vaginal insert for 14 days were 3.6 pg/mL and 4.6 pg/mL, respectively, which was not statistically different from placebo (4.3 pg/mL). After twice weekly use for 84 days, there was no difference in serum estradiol levels compared with baseline or placebo.

Serum estradiol levels associated with use of vaginal estradiol cream are derived from older data using higher doses and less-sensitive assays that lack accuracy for lower estrogen levels.<sup>129</sup> Use of estradiol cream 0.5 mg (500  $\mu$ g) daily for 3 weeks resulted in no change in serum estradiol levels.<sup>130</sup> In contrast, another study showed that daily use of estradiol cream 0.2 mg (200  $\mu$ g) daily resulted in serum estradiol levels that rose from a baseline of 16.6 pg/mL to 37.2 pg/mL after 3 weeks of use.<sup>131</sup> Use of 0.3 mg conjugated estrogens (CE) cream 3 times weekly for 6 months produced no change in serum estradiol or estrone levels.<sup>132</sup> Of note, CE contains a significant number of compounds, some estrogenic and some antiestrogenic, so serum estradiol and estrone levels after use of CE may not reflect actual estrogenic activity. Vaginal bleeding, breast pain, and nausea have been reported in some trials of vaginal estrogen cream. These symptoms are dose related and suggest that the dose was large enough to result in significant systemic absorption.

Adverse events associated with use of vaginal ET include vaginal discharge, vulvovaginal candidiasis, vaginal bleeding, and breast pain. Differing AE profiles may reflect variations in product formulation and dose.<sup>133,134</sup>

The risks typically associated with systemic ET, including breast and endometrial cancer and cardiovascular disease (CVD), have been evaluated in several trials of vaginal ET. Clinical trial data beyond 1 year are lacking, however, because the longest duration of any RCT was 52 weeks.<sup>135</sup> Endometrial safety was assessed in two systematic reviews that included RCTs and large observational studies.<sup>136,137</sup> In 20 RCTs, 2,983 women were exposed to vaginal ET for up to 1 year. There was one case of endometrial cancer (0.03%) and 12 cases of endometrial hyperplasia (0.4%). The cases were sporadic and their incidence similar to the baseline rate in the general population. A 2016 Cochrane review of RCTs reported no significant differences among vaginal estrogen formulations in terms of endometrial thickness or hyperplasia or the proportion of women with AEs.<sup>112</sup> Large observational studies evaluating longer exposures to vaginal ET identified no increase in endometrial cancer. In the Women's Health Initiative-Observational Study, the rate of endometrial cancer was not statistically different in users of vaginal ET compared with nonusers (1.3 vs 1 case per 1,000 woman-years, respectively). Thus, occurrence of endometrial cancer and hyperplasia with low-dose vaginal ET use is rare and consistent with rates in the general population.

The risk of venous thromboembolism (VTE) was not increased with vaginal ET use in a 2016 Cochrane review, a 2020 systematic review of RCTs, and three large observational studies.<sup>112,135,137-139</sup> Of note, systematic, prospective data for women at high risk of VTE are lacking.

A prospective cohort study of approximately 45,000 women in the Women's Health Initiative Observational Study examined risks associated with vaginal ET use. Outcomes assessed included coronary heart disease (CHD), invasive breast cancer, stroke, pulmonary embolism, hip fracture, colorectal cancer, endometrial cancer, and death. The findings were very reassuring, with no increased risk of CVD or cancer in postmenopausal women using vaginal estrogens.<sup>135</sup> Another prospective cohort study of approximately 54,000 postmenopausal women in the Nurses' Health Study also was very reassuring regarding the safety of vaginal ET. There was no increase in health outcomes assessed with vaginal ET use, including CVD (total myocardial infarction, stroke, pulmonary embolism/VTE), hip fracture, and cancer (total invasive, breast, endometrial, ovarian, and colorectal).<sup>138</sup> In a 2019 meta-analysis, investigators used individual participant data from 58 observational studies reported between 1992 and 2018 to assess associations between hormone therapy and breast cancer.<sup>140</sup> Use of vaginal estrogen was not found to be associated with risk of breast cancer.

#### *Potential contraindications to vaginal estrogen therapy*

Although most women with GSM are candidates for low-dose vaginal ET, use is contraindicated in women with undiagnosed vaginal/uterine bleeding and should be used with caution in women with estrogen-dependent neoplasia. Management of GSM in women with nonhormone-dependent cancers is similar to that for women without a cancer history. Low-dose vaginal ET has not been studied in women at increased risk of thrombosis, but may be used with caution given minimal systemic absorption, the absence of a hepatic first-pass effect, and minimal, if any, effect on prothrombotic factors. Of note, in large observational studies, neither vaginal estrogen nor systemic transdermal formulations of ET have been associated with an increased risk of VTE.<sup>139</sup>

Although circulating estrogen concentrations generally remain within the menopause range with low-dose vaginal ET, the package insert for these products includes the same boxed warning regarding risk of endometrial cancer, breast cancer, cardiovascular disorders, and probable dementia that accompanies systemic HT products. Women must be educated about the differences between low-dose vaginal and systemic ET and be prepared for the boxed warning, or else they may not initiate prescribed treatment.

#### **Vaginal estrogen products**

Several low-dose vaginal estrogen products have been government approved for use in the United States and Canada, including cream (estradiol, estrone, and conjugated estrogens), a slow-release estradiol intravaginal ring, and an estradiol vaginal tablet and insert (Table 2).<sup>89-97</sup> Vaginal estrogen creams are generally used two to three times weekly, estradiol tablets and inserts used twice weekly, and the estradiol ring changed every 3 months. Estrogen creams, tablets and inserts are used daily for 2 weeks at the initiation of treatment for more rapid improvement in symptoms (Table 2).<sup>89-97</sup> One vaginal ET



product (Femring) delivers a *systemic* dose of estradiol and is approved for the treatment of VMS in addition to GSM.<sup>141</sup> Femring should not be confused with Estring, which delivers a low dose of estradiol and is indicated only for GSM. There are no data to suggest an advantage for initial use of combined systemic and vaginal estrogen in cases of severe GSM.

Therapy with low-dose vaginal estrogen can be individualized to identify the lowest dose and frequency of use that provides the desired effect. Although efficacy is similar among the available products, estrogen creams dispensed with an applicator may offer more immediate soothing relief of symptoms, possibly because of the emollient nature of the carrier. Another potential advantage of the creams is that they can be digitally applied directly to the vulvar and vestibular tissues. However, some women consider the creams messy, and some report sensitivity to the vehicle used in the creams. With estrogen cream delivery, the user has the responsibility of preparing the dose because the amount of cream inserted is not in a prepackaged dosing unit—potentially leading to use of higher-than-recommended doses. The clinical implications of potential male partner estrogen absorption remain unknown.

Low-dose estradiol tablets and inserts are convenient, fixed-dose vaginal estrogen formulations. Although two doses of the vaginal tablet (25 µg and 10 µg) were shown to be effective, only the lower dose (10 µg) is available in the United States and Canada.<sup>101,102,107-109,111,142</sup> There are two approved doses of the vaginal insert (4 µg and 10 µg), with the 4-µg dose providing the lowest available formulation of vaginal ET.<sup>143-145</sup>

The sustained-release, low-dose estradiol vaginal ring provides 90 days of continuous estradiol. Effective relief of genitourinary symptoms, including dyspareunia, dysuria, and urge incontinence, has been consistently documented in RCTs with this estrogen delivery system.<sup>99,100,103-107</sup> The estradiol ring may change position or dislodge with bowel movements, Valsalva maneuvers, douching, or vaginal sexual penetration, particularly in women with uterovaginal prolapse or hysterectomy. Vaginal ring users are encouraged to remove and replace their own vaginal rings unless discomfort or limited dexterity makes such self-care difficult. The ring can remain in the vagina during sexual activity. There are no data to suggest an allergic reaction to the silicone product. If there is significant stenosis of the vagina, regular use of graduated vaginal dilators after initiation of estrogen cream, tablet, or insert may be necessary before an estrogen ring can be inserted.

Given similar efficacy among vaginal estrogen formulations, women should be provided with information on all options, with personal preference guiding choice. Although some women prefer estrogen creams to allow for vulvar and vestibular as well as vaginal application, others find creams messy and dislike cleaning the applicator after use. Because creams do not provide a specific, fixed dose of estrogen, other options may be preferred if careful dosing and predictable results of serum estrogen levels are desired. Vaginal estradiol

tablets and inserts are convenient, requiring only twice weekly application after 2 weeks of daily use. The tablet is placed in the vagina with a plastic applicator, whereas the insert is placed with a finger. Preference for insertion method may determine product choice. For women who are comfortable using a vaginal ring, this formulation is convenient, requiring placing a new ring only four times yearly. Vaginal estrogen formulations are often costly, and variation in price, depending on a woman's particular insurance coverage, also may be a factor in product choice.

### Vaginal dehydroepiandrosterone

Dehydroepiandrosterone (also known as prasterone) is a steroid hormone that is an intermediate in the biosynthesis of androgens and estrogens. A low-dose DHEA vaginal insert used daily with an applicator is approved in the United States and Canada for the treatment of moderate to severe dyspareunia in menopausal women (Table 2).<sup>89-97</sup> Dehydroepiandrosterone is transformed by vaginal mucosal cells to estrogens, including estradiol, and to androgens, including testosterone.<sup>146</sup> Twelve-week RCTs have demonstrated the efficacy of DHEA 6.5 mg daily in improving the VMI, vaginal pH, dyspareunia, and vaginal dryness in menopausal women with GSM. Vaginal discharge was the most common AE, reported by 6% of study participants. In 422 women receiving DHEA for 52 weeks, endometrial sampling demonstrated inactive or atrophic endometrium in all participants.<sup>147</sup>

### Ospemifene

Ospemifene is an estrogen agonist/antagonist and the only orally available product approved for treatment of vaginal dryness and moderate to severe dyspareunia. It is available in the United States, but not in Canada.<sup>97,148</sup> Twelve-week RCTs have demonstrated the efficacy of ospemifene 60 mg daily in improving VMI, vaginal pH, dyspareunia, vaginal dryness, and genital exam findings.<sup>149-151</sup> A 52-week efficacy and safety extension study in 180 women showed sustained improvements on visual examination of the vagina, with no cases of VTE, endometrial hyperplasia, or cancer.<sup>152</sup> Vasomotor symptoms were the most common AE, with rates of 2% in the placebo group and 7.2% in the group taking 60 mg of ospemifene. Ospemifene was shown to reduce recurrent UTIs in a 6-month retrospective observational study.<sup>153</sup>

The prescribing information for ospemifene contains precautions similar to those for estrogens and other estrogen agonist/antagonists, including an increased risk of endometrial cancer and CVD.<sup>97</sup> With regard to breast cancer, labeling states that ospemifene should not be used in women with known or suspected breast cancer because the drug has not been adequately studied in this group. Ospemifene has, however, demonstrated antiestrogenic activity in preclinical models of breast cancer.<sup>154</sup> In *ex vivo* human breast tissue, ospemifene inhibited proliferation and opposed stimulation caused by estradiol similar to but not as potently as the estrogen agonist/antagonists tamoxifen and raloxifene.<sup>155</sup> Ospemifene 60 mg has been associated with decreased risk

for breast cancer and breast cancer recurrence in preliminary studies.<sup>156</sup>

### Duration of therapy and monitoring

Improvement in GSM symptoms typically occurs within a few weeks of starting therapy<sup>157</sup>; however, treatment for 12 weeks may be needed for maximum benefit. In the absence of contraindications, therapy should be continued as long as needed for symptom management as symptoms will recur upon discontinuation. Clinical trial safety data are limited to 1 year, but observational studies demonstrate safety with long-term use.

Based on available limited safety data, use of a progestogen<sup>112,126</sup> and routine endometrial surveillance<sup>112,158,159</sup> are not recommended in low-risk women using low-dose vaginal ET. Women at increased risk of endometrial cancer because of obesity or diabetes may warrant endometrial surveillance. Because uterine bleeding is generally a sign of endometrial proliferation, any spotting or bleeding requires a thorough evaluation that may include transvaginal ultrasound (TVU) and/or endometrial biopsy.

### Testosterone

Topical testosterone cream has been used for the treatment of vulvovaginal conditions, including lichen sclerosus and vestibulodynia, despite limited efficacy data.<sup>160,161</sup> Although not government approved for this indication, there are limited data supporting the use of vaginal testosterone cream for the treatment for GSM. A 4-week pilot trial of 20 postmenopausal women with breast cancer found that vaginal testosterone (150 µg and 300 µg) improved dyspareunia, vaginal dryness, and VMI without increasing estradiol; median testosterone level increased from 15.5 ng/dL to 21.5 ng/dL ( $P = .02$ ).<sup>162</sup> A 12-week RCT in 76 menopausal women taking AIs after treatment for early stage breast cancer who reported vaginal dryness, dyspareunia, or reduced libido compared the low-dose estradiol vaginal ring with compounded vaginal testosterone cream. Symptoms of GSM and sexual desire improved in both treatment arms. The observation that levels of serum estradiol were increased in trial participants at baseline complicates interpretation of these findings.<sup>163</sup> Existing clinical trial data are insufficient to recommend the use of vaginal testosterone for GSM.<sup>164</sup> Longer and larger studies are needed to assess safety and efficacy.

### Energy-based therapies

Vulvovaginal energy-based devices including lasers (fractional CO<sub>2</sub>, Erbium:YAG) and radio-frequency devices are under investigation as treatments for GSM, but none have FDA approval for this indication. In a 2018 Safety Communication, FDA issued a public warning about the use of these devices for vaginal cosmetic purposes, stating that the effectiveness and safety of the devices have not yet been established.<sup>165</sup>

Vulvovaginal energy-based devices are thought to improve vaginal health by causing microtrauma, which induces collagen

formation, angiogenesis, and epithelial thickening. The fractional CO<sub>2</sub> laser has demonstrated safety and efficacy in tissues of the skin, face, and neck.<sup>166-169</sup> Using a probe adapted to the vagina, fractional CO<sub>2</sub> vaginal laser therapy induces similar morphologic changes in the vagina, and data from small studies support improvement in GSM symptoms of vaginal dryness and dyspareunia.<sup>170-178</sup> Several RCTs have compared laser therapy to vaginal ET. Overall, no treatment was superior to another, and the studies were not designed to assess noninferiority.<sup>179-182</sup> Radiofrequency devices are nonablative and emit focused electromagnetic waves that heat the superficial layers of the tissue. Several RCTs evaluating the efficacy of energy-based devices in the treatment of GSM are in progress.

### Safety

Adverse events associated with energy-based therapies include discomfort during treatments, vaginal scarring, vaginal lacerations on resumption of intercourse, and persistent and/or worsening dyspareunia.<sup>183</sup> These treatments are costly and generally not covered by insurers.

Consensus statements regarding the use of energy-based therapies for GSM treatment have been published by several professional societies summarizing the small but growing body of evidence as well as concerns about safety.<sup>184-187</sup> Additional randomized, prospective, sham-controlled trials of adequate size and scope are necessary before these therapies can be routinely recommended for treatment of GSM.

### Treatment considerations in women with breast cancer

Treatment of GSM in women with breast cancer can be complicated by 1) adjuvant treatment (AIs or tamoxifen), which lower estrogen concentrations or antagonize estrogen effects; 2) product labeling; 3) limited clinical trial data in patients with breast cancer or survivors; and 4) absence of agreement between the oncology community and other practitioners involved in genitourinary and sexual healthcare. Many women with breast cancer and GSM will benefit from the regular use of vaginal moisturizers, lubricants for sexual activity, and PFPT. For persistent symptoms, other therapies may be beneficial, including topical lidocaine, low-dose vaginal ET, vaginal DHEA, ospemifene, and vaginal energy-based therapies.<sup>188-191</sup>

For women with breast cancer, low-dose vaginal ET is contraindicated according to FDA class labeling. However, off-label use of several products may be acceptable because of their very low systemic absorption.<sup>192</sup> Low-dose vaginal ET formulations, including the estradiol tablet, insert, and ring, result in serum estradiol within the postmenopausal range and similar to placebo.<sup>145,146</sup> Several organizations, including the American College of Obstetricians and Gynecologists, have endorsed the use of low-dose vaginal estrogens in women with breast cancer, including ER-positive disease. A systematic review and meta-analysis also suggests safety, based on the use of low-dose vaginal ET in survivors of breast cancer using concomitant AIs.<sup>193</sup> Many oncologists allow the use of low-dose vaginal ET or vaginal DHEA in their patients with

breast cancer when GSM symptoms persist after trials of nonhormone interventions and QOL is adversely affected.

Use of vaginal DHEA for GSM in women with breast cancer is not contraindicated, but US labeling advises caution because estrogen is a metabolite of DHEA.<sup>95</sup> Although vaginal DHEA has not been studied in women with a history of breast cancer, levels of estradiol and testosterone remain within the postmenopause range.<sup>194</sup>

Ospemifene is not recommended for treatment of GSM in women with known or suspected breast cancer because the drug has not been adequately studied in this group. Preliminary data on ospemifene suggest both a decreased risk of incident breast cancer and a reduced risk of breast cancer recurrence with this therapy.<sup>156</sup>

Clinical trials of laser therapy for GSM in survivors of breast cancer provide limited evidence for safety and efficacy in this patient population.<sup>195-197</sup> These studies generally do not have either a positive or sham control, a shortcoming of many of the studies on these devices.

### Education

Healthcare providers should educate women about GSM and the urogenital changes that often occur with menopause. Many women are unaware that vaginal dryness, recurrent UTIs, discomfort with sexual activity, and other GSM symptoms are a consequence of estrogen deficiency. Unlike VMS that typically improve with time, GSM symptoms often worsen in the absence of treatment. Women also may not know that effective and safe OTC and prescription therapies are available. Women who are sexually active are more likely to notice GSM symptoms and seek care, but sexually inactive women also will benefit from education about GSM. Women who are concerned about future urogenital function may consider *preventive* use of lubricants, moisturizers, vaginal dilators, or prescription therapies, but there is no evidence to support this approach. It is unknown whether treatment to preserve sexual function or prevent the future occurrence of GSM is indicated in the absence of urogenital symptoms.

### CONCLUSIONS AND RECOMMENDATIONS

- Education about and screening for GSM is recommended for perimenopausal and postmenopausal women. [Level C]
- First-line therapies for women with GSM include non-hormone lubricants with sexual activity and regular use of long-acting vaginal moisturizers. [Level A]
- For women with moderate to severe GSM and those who do not respond to lubricants and moisturizers, several safe and effective options are available:
  - Low-dose vaginal ET [Level A]
  - Vaginal DHEA [Level A]
  - Ospemifene [Level A]
  - Systemic ET (when VMS are also present) [Level A]
- For women with a history of breast or endometrial cancer, management depends on a woman's preferences, symptom severity, and understanding of potential risks after consultation with her oncologist. [Level C]

- Although product labeling for low-dose vaginal ET notes risks associated with systemic HT (including CHD, stroke, VTE, breast and endometrial cancer), these risks are highly unlikely given minimal systemic absorption and reassuring findings from clinical trials and observational studies. [Level B]
- Use of a progestogen is not recommended with low-dose vaginal ET, although women at increased risk of endometrial cancer may warrant endometrial surveillance. Endometrial safety clinical trial data are not available for use longer than 1 year, although observational studies are reassuring regarding longer-term use. [Level B]
- Routine endometrial surveillance is not recommended for asymptomatic women using low dose vaginal ET. Transvaginal ultrasound or intermittent progestogen therapy may be considered for women at increased risk of endometrial cancer. [Level C]
- Spotting or bleeding in a postmenopausal woman requires a thorough evaluation that may include TVU and/or endometrial biopsy. [Level A]
- Energy-based therapies, including vaginal laser and radio-frequency devices, require long-term, sham-controlled safety and efficacy studies before their routine use can be recommended. [Level C]
- Therapy for GSM should be continued, with appropriate clinical follow up, for as long as bothersome symptoms are present. [Level C]

### Strength of Recommendation

- Level A Supported by sufficient, consistent scientific evidence
- Level B Supported by limited or inconsistent evidence
- Level C Based primarily on expert opinion

### ACKNOWLEDGMENTS AND DISCLOSURES

NAMS appreciates the contributions of the NAMS 2020 GSM Position Statement Editorial Panel and the work of the NAMS Board of Trustees on this position statement. The authors, planners, reviewers, and staff who were in a position to control and influence the content of this activity were required to disclose any relevant financial relationship (s) of the individuals or their spouse/partner that had occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. After reviewing disclosures from all involved in the content of this activity, NAMS has implemented mechanisms to identify and resolve any conflicts for all involved, including review of content by those who had no conflicts of interest.

**Acknowledgments:** The NAMS 2020 GSM Position Statement Editorial Panel: Stephanie S. Faubion, MD, MBA, FACP, NCMP, IF, *Lead*; Professor and Chair, Department of Medicine, Mayo Clinic, Jacksonville, Florida; Penny and Bill George Director, Mayo Clinic Center for Women's Health; Medical Director, The North American Menopause Society, Pepper Pike, Ohio. Sheryl A. Kingsberg, PhD, *Lead*;



Chief, Division of Behavioral Medicine, University Hospitals Cleveland Medical Center; MacDonald Women's Hospital; Professor, Departments of Reproductive Biology and Psychiatry, Case Western Reserve University School of Medicine, Cleveland, Ohio. Amanda L. Clark, MD, MCR, NCMP; Affiliate Investigator and Urogynecology Physician, Female Pelvic Medicine and Reconstructive Surgery, Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon. Andrew M. Kaunitz, MD, FACOG, NCMP; University of Florida Term Professor and Associate Chairman, Department of Obstetrics and Gynecology; University of Florida College of Medicine—Jacksonville; Medical Director and Director of Menopause and Gynecologic Ultrasound Services, University of Florida Women's Health Specialists—Emerson, Jacksonville, Florida. Susan Kellogg Spadt, PhD, CRNP, IF, FCST, CSC; Director of Female Sexual Medicine, Center for Pelvic Medicine, Drexel University College of Medicine; Widener University College of Human Service Professions; Academic Urology Center for Pelvic Medicine, Philadelphia, Pennsylvania. Lisa C. Larkin, MD, FACP, NCMP, IF; Lisa Larkin and Associates, Internal Medicine and Women's Health, Cincinnati, Ohio. Caroline M. Mitchell, MD, MPH; Associate Professor of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School; Director, Vulvovaginal Disorders Program, Massachusetts General Hospital, Boston, Massachusetts. Jan L. Shifren, MD, NCMP; Director, Midlife Women's Health Center, Massachusetts General Hospital; Vincent Trustees Professor of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, Massachusetts. James A. Simon, MD, CCD, NCMP, IF, FACOG; Clinical Professor, George Washington University; Medical Director, Women's Health and Research Consultants, Washington, DC.

NAMS recognizes the contributions of Ms. Carolyn Develen, NAMS Chief Operating Officer, and Ms. Kathy Method, MA, NAMS Communications Manager.

This position statement was reviewed and approved by the 2019-2020 NAMS Board of Trustees: Rebecca C. Thurston, PhD, President; Director, Women's Biobehavioral Health Laboratory; Professor of Psychiatry, Psychology, Epidemiology, and Clinical and Translational Science; University of Pittsburgh, Pittsburgh, Pennsylvania. Hadine Joffe, MD, MSc, President-Elect; Executive Director, Mary Horrigan Connors Center for Women's Health and Gender Biology; Paula A. Johnson Associate Professor of Psychiatry in the Field of Women's Health; Harvard Medical School; Vice Chair for Psychiatry Research, Department of Psychiatry; Brigham and Women's Hospital, Dana Farber Cancer Institute; Harvard Medical School, Boston, Massachusetts. James H. Liu, MD, NCMP, Immediate Past President; Arthur H. Bill Professor and Chair; Department of Obstetrics and Gynecology; University Hospitals Cleveland Medical Center; MacDonald Women's Hospital; Department of Reproductive Biology; Case Western Reserve University School of Medicine, Cleveland, Ohio. Lisa C. Larkin, MD, FACP, NCMP, IF, Treasurer; Lisa Larkin and Associates, Internal Medicine and

Women's Health, Cincinnati, Ohio. Carolyn J. Crandall, MD, MS, FACP, NCMP, FASBMR, Secretary; Professor of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, California. Stephanie S. Faubion, MD, MBA, FACP, NCMP, IF, Professor and Chair, Department of Medicine, Mayo Clinic, Jacksonville, Florida; Penny and Bill George Director, Mayo Clinic Center for Women's Health; Medical Director, The North American Menopause Society, Pepper Pike, Ohio. Lisa Astalos Chism, DNP, APRN, NCMP, FAANP; Clinical Director, Women's Wellness Clinic; Sexual Health Counselor and Educator; Karmanos Cancer Institute; Adjunct Assistant Professor, Department of Surgery; Wayne State University School of Medicine, Detroit, Michigan. Samar R. El Khoudary, PhD, MPH, BPharm, FAHA; Associate Professor, Department of Epidemiology, Epidemiology Data Center, University of Pittsburgh, Pittsburgh, Pennsylvania. Michael R. McClung, MD, FACP, FASBMR, FACE; Founding Director, Oregon Osteoporosis Center, Portland, Oregon, Professorial Fellow, Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia. Susan D. Reed, MD, MPH; Research Director, Women's Reproductive Health Research Program; Professor and Vice Chair, Department of Obstetrics and Gynecology; Adjunct Professor, Epidemiology, University of Washington School of Medicine, Seattle, Washington. Nanette F. Santoro, MD; Professor and E. Stewart Taylor Chair of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado. Chrisandra L. Shufelt, MD, MS, FACP, NCMP; Associate Director, Barbra Streisand Women's Heart Center and Preventive and Rehabilitative Cardiac Center; Director, Women's Hormone and Menopause Program; Associate Professor of Medicine, Cedars-Sinai Medical Center, Los Angeles, California. Claudio N. Soares, MD, PhD, FRCPC, MBA; Professor and Head, Department of Psychiatry, Queen's University School of Medicine; Executive Director, Research and Innovation, Providence Care Hospital; Executive Lead, Strategy and New Partnerships, Canadian Biomarker Integration Network in Depression (CAN-BIND), St. Michael's Hospital, Kingston, Ontario, Canada. Isaac Schiff, CM, MD, Editor-in-Chief, *Menopause*; Joe Vincent Meigs Distinguished Professor of Gynecology, Harvard Medical School; Chief, Department of Obstetrics and Gynecology, Emeritus; The Women's Care Division, Massachusetts General Hospital, Boston, Massachusetts.

**Financial disclosures/conflicts of interest:** For the GSM Position Statement Editorial Panel: Dr. Faubion and Dr. Shifren report no relevant financial relationships. Dr. Kingsberg reports Consultant/Advisory Board for Amag, Astellas, Dare, Duchesney, Endoceutics, Lupin, Materna, Mitsubishi Tanaba, Ovaco, Palatin Technologies, Pfizer, Sprout, Strategic Science Technologies, TherapeuticsMD, and Viveve; Speaker for Amag and Therapeutics MD. Dr. Clark reports Consulting Fees for Butler Snow LLC; Grant Funding (paid to institution) from Pfizer. Dr. Kaunitz reports



Consultant for Amag, Mithra, Pfizer; Clinical Trial Support (paid to institution) from Endoceutics, Mithra. Dr. Kellogg Spadt reports Speaker for Amag, Bonafide, TherapeuticsMD. Dr. Larkin reports Consultant/Advisory Board for Amag, Lupin, Procter & Gamble, TherapeuticsMD; Speakers' Bureau for Amag, Amgen, TherapeuticsMD. Dr. Mitchell reports Spouse Employee at Sanofi Genzyme; Consulting for Scynexis. Research Funding from Merck. Dr. Simon reports Research/Grant Support from AbbVie, Bayer Healthcare, Endoceutics, GTx, Inc, Ipsen, Myovant Sciences; Consultant for AbbVie, Amag, Bayer HealthCare, CEEK Enterprises, Covance, Dare Bioscience, Duchesnay, Hologic, KaNDy/NeRRe Therapeutics, Mitsubishi Tanabe Pharma Development America, Shionogi, Sprout2, TherapeuticsMD; Speaker for AbbVie, Amag, Duchesnay, TherapeuticsMD. For additional contributors, Ms. Develen and Ms. Method report no relevant financial relationships.

For the NAMS Board of Trustees members who were not members of the Editorial Panel: Dr. Crandall, Dr. El Khoudary, Dr. Shufelt, and Dr. Schiff report no relevant financial relationships. Dr. Thurston reports Consultant/Advisory Board for Astellas, Pfizer, Procter & Gamble, Virtue Health. Dr. Joffe reports Consultant/Advisory Board for Esai, Jazz, Merck, NeRRe/KaNDy, Sojournix; Grant/Research Support from Brigham and Women's Hospital Funds, Merck, NIH, NIA, NIMH, NCI, NeRRe/KaNDy, Pfizer, QUE Oncology, V Foundation; spouse employee for Merck, Arsenal Biosciences and Tango, consulting and equity. Dr. Liu reports Consultant/Advisory Board for Allergan, Amag, Astellas, Bayer, Daré, Ferring, Lupin, Mitsubishi, TherapeuticsMD; Research Grants from AbbVie, Allergan, Amag, Astellas, Femasys. All funds paid to the institution. Dr. Chism reports Consultant/Advisory Board for Hologic; Speakers' Bureau for Amag, Astellas, JDS Therapeutics; Royalties/Patents for Jones and Bartlett Publishing. Dr. McClung reports Consultant/Advisory Board for Amgen, Myovant; Speakers' Bureau for Amgen, Radius. Dr. Reed reports Grant/Research Support from Bayer, NIH; Royalties/Patents from *UpToDate*. Dr. Santoro reports Consultant/Advisory Board for Ansh Labs, Menogenix, Ogeda/Astellas; Stock/Ownership for Menogenix. Dr. Soares reports Consultant/Advisory Board for Lundbeck, Otsuka; Grant/Research Support from Ontario Research Fund, Ontario Brain Institute, AHSC AFP Innovation Fund.

## REFERENCES

- Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. *Maturitas* 2004;49:292-303.
- Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. *Menopause* 2008;15:661-666.
- Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. *J Sex Med* 2009;6:2133-2142.
- Palma F, Volpe A, Villa P, Cagnacci A; Writing group of AGATA study. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study. *Maturitas* 2016;83:40-44.
- Simon JA, Kokot-Kierpa M, Goldstein J, Nappi RE. Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey. *Menopause* 2013;20:1043-1048.
- Kingsberg SA, Krychman M, Graham S, Bernick B, Mirkin S. The Women's EMPOWER Survey: identifying women's perceptions on vulvar and vaginal atrophy and its treatment. *J Sex Med* 2017;14:413-424.
- Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (Real Women's Views of Treatment Options for Menopausal Vaginal Changes) survey. *J Sex Med* 2013;10:1790-1799.
- Krychman M, Graham S, Bernick B, Mirkin S, Kingsberg SA. The women's EMPOWER survey: women's knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. *J Sex Med* 2017;14:425-433.
- Nappi RE, Palacios S, Bruyniks N, Particco M, Panay N; EVES Study Investigators. The burden of vulvovaginal atrophy on women's daily living: implications on quality of life from a face-to-face real-life survey. *Menopause* 2019;26:485-491.
- Shifren JL, Zincavage R, Cho EL, et al. Women's experience of vulvovaginal symptoms associated with menopause. *Menopause* 2018;26:341-349.
- Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. *Climacteric* 2012;15:267-274.
- Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. *Menopause* 2014;21:1063-1068.
- Shifren JL. Genitourinary syndrome of menopause. *Clin Obstet Gynecol* 2018;61:508-516.
- Robinson D, Toozs-Hobson P, Cardozo L. The effect of hormones on the lower urinary tract. *Menopause Int* 2013;19:155-162.
- Chen GD, Oliver RH, Leung BS, Lin LY, Yeh J. Estrogen receptor alpha and beta expression in the vaginal walls and uterosacral ligaments of premenopausal and postmenopausal women. *Fertil Steril* 1999;71:1099-1102.
- Gebhart JB, Rickard DJ, Barrett TJ, et al. Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women. *Am J Obstet Gynecol* 2001;185:1325-1330.
- Hodgins MB, Spike RC, Mackie RM, MacLean AB. An immunohistochemical study of androgen, oestrogen and progesterone receptors in the vulva and vagina. *Br J Obstet Gynaecol* 1998;105:216-222.
- Griebing TL, Liao Z, Smith PG. Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women. *Menopause* 2012;19:630-635.
- Grodeski GI. Estrogen modulation of epithelial permeability in cervical-vaginal cells of premenopausal and postmenopausal women. *Menopause* 2007;14:1012-1019.
- Bachmann GA, Cheng RJ, Rovner E. Vulvovaginal complaints. In: Lobo RA, editor. *Treatment of the Postmenopausal Woman: Basic and Clinical Aspects*, 3rd ed. Burlington, MA: Academic Press; 2007:263-270.
- Pudney J, Quayle AJ, Anderson DJ. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. *Biol Reprod* 2005;73:1253-1263.
- Meditz AL, Moreau KL, MaWhinney S, et al. CCR5 expression is elevated on endocervical CD4+ T cells in healthy postmenopausal women. *J Acquir Immune Defic Syndr* 2012;59:221-228.
- White HD, Yeaman GR, Givan AL, Wira CR. Mucosal immunity in the human female reproductive tract: cytotoxic T lymphocyte function in the cervix and vagina of premenopausal and postmenopausal women. *Am J Repro Immunol* 1997;37:30-38.
- Sivro A, Lajoie J, Kimani J, et al. Age and menopause affect the expression of specific cytokines/chemokines in plasma and cervical lavage samples from female sex workers in Nairobi, Kenya. *Immun Ageing* 2013;10:42.
- Thoma ME, Gray RH, Kiwanuka N, et al. Longitudinal changes in vaginal microbiota composition assessed by gram stain among never sexually active pre- and postmenarcheal adolescents in Rakai, Uganda. *J Pediatr Adolesc Gynecol* 2011;24:42-47.
- Brotman RM, Shardell MD, Gajer P, et al. Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. *Menopause* 2014;21:450-458.
- Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. *Proc Natl Acad Sci U S A* 2011;108:4680-4687.

28. Lamont RF, Sobel JD, Akins RA. The vaginal microbiome: new information about genital tract flora using molecular based techniques. *BJOG* 2011;118:533-549.
29. Lai SK, Hida K, Shukair S, et al. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. *J Virol* 2009;83:11196-11200.
30. Wiesenfeld HC, Hillier SL, Krohn MA, Landers DV, Sweet RL. Bacterial vaginosis is a strong predictor of *Neisseria gonorrhoeae* and *Chlamydia trachomatis* infection. *Clin Infect Dis* 2003;36:663-668.
31. Chernes TL, Meyn LA, Krohn MA, Lurie JG, Hillier SL. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. *Clin Infect Dis* 2003;37:319-325.
32. Pybus V, Onderdonk AB. Microbial interactions in the vaginal ecosystem, with emphasis on the pathogenesis of bacterial vaginosis. *Microbes Infect* 1999;1:285-292.
33. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. *J Infect Dis* 1999;180:1863-1868.
34. Gupta K, Stapleton AE, Hooton TM, Roberts PL, Fennell CL, Stamm WE. Inverse association of H<sub>2</sub>O<sub>2</sub>-producing lactobacilli and vaginal *Escherichia coli* colonization in women with recurrent urinary tract infections. *J Infect Dis* 1998;178:446-450.
35. Gosmann C, Anahtar MN, Handley SA, et al. Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. *Immunity* 2017;46:29-37.
36. Roy S, Caillouette JC, Roy T, Faden JS. Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis. *Am J Obstet Gynecol* 2004;190:1272-1277.
37. Hillier SL, Lau RJ. Vaginal microflora in postmenopausal women who have not received estrogen replacement therapy. *Clin Infect Dis* 1997;25:S123-S126.
38. Hummelen R, Macklaim JM, Bisanz JE, et al. Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness. *PLoS One* 2011;6:e26602.
39. Shen J, Song N, Williams CJ, et al. Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. *Sci Rep* 2016;6:24380.
40. Mitchell CM, Srinivasan S, Zhan X, et al. Vaginal microbiota and genitourinary menopausal symptoms: a cross-sectional analysis. *Menopause* 2017;24:1160-1166.
41. Brotman RM, Ravel J, Cone RA, Zenilman JM. Rapid fluctuation of the vaginal microbiota measured by Gram stain analysis. *Sex Transm Infect* 2010;86:297-302.
42. Cauci S, Driussi S, De Santo. et al. Prevalence of bacterial vaginosis and vaginal flora changes in peri- and postmenopausal women. *J Clin Microbiol* 2002;40:2147-2152.
43. Gliniewicz K, Schneider GM, Ridenhour BJ, et al. Comparison of the vaginal microbiomes of premenopausal and postmenopausal women. *Front Microbiol* 2019;10:193.
44. Galhardo CL, Soares JM, Simoes RS, Haidar MA, Rodrigues de Lima G, Baracat EC. Estrogen effects on the vaginal pH, flora and cytology in late postmenopause after a long period without hormone therapy. *Clin Exp Obstet Gynecol* 2006;33:85-89.
45. Heineman C, Reid G. Vaginal microbial diversity among postmenopausal women with and without hormone replacement therapy. *Can J Microbiol* 2005;51:777-781.
46. Nappi RE, Martini E, Cucinella L, et al. Addressing vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause (GSM) for healthy aging women. *Front Endocrinol (Lausanne)* 2019;10:561.
47. Kagan R, Kellogg-Spadt S, Parish SJ. Practical treatment considerations in the management of genitourinary syndrome of menopause. *Drugs Aging* 2019;36:897-908.
48. Pacello PC, Yela DA, Rabelo S, Giraldo PC, Benetti-Pinto CL. Dyspareunia and lubrication in premature ovarian failure using hormonal therapy and vaginal health. *Climacteric* 2014;17:342-347.
49. de Almeida DM, Benetti-Pinto CL, Makuch MY. Sexual function of women with premature ovarian failure. *Menopause* 2011;18:262-266.
50. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. *JAMA* 2005;294: 91-96.
51. Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ. Ovarian androgen production in postmenopausal women. *J Clin Endocrinol Metab* 2007;92:3040-3043.
52. Taylor CE, Meisel JL. Management of breast cancer therapy-related sexual dysfunction. *Oncology* 2017;31:726-729.
53. Conde DM, Pinto-Neto AM, Cabello C, Sá DS, Costa-Paiva L, Martinez EZ. Menopause symptoms and quality of life in women aged 45 to 65 years with and without breast cancer. *Menopause* 2005;12:436-443.
54. Greendale GA, Petersen L, Zibecchi L, Ganz PA. Factors related to sexual function in postmenopausal women with a history of breast cancer. *Menopause* 2001;8:111-119.
55. Knopf MT. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. *Oncologist* 2006;11:96-110.
56. Burwell SR, Case LD, Kaelin C, Avis NE. Sexual problems in younger women after breast cancer surgery. *J Clin Oncol* 2006;24:2815-2821.
57. Arora NK, Gustafson DH, Hawkins RP, et al. Impact of surgery and chemotherapy on the quality of life of younger women with breast carcinoma: a prospective study. *Cancer* 2001;92:1288-1298.
58. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. *J Natl Cancer Inst* 2000;92:1054-1064.
59. Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. *Menopause* 2013;20:162-168.
60. Bradford A. Sexual outcomes of aromatase inhibitor therapy in women with breast cancer: time for intervention. *Menopause* 2013;20:128-129.
61. Kaunitz AM. Sexual dysfunction with aromatase inhibitor therapy: an underestimated problem? *NEJM Journal Watch: Women's Health* 2013; 5-6.
62. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A; ATAC Trialsta9 Group. Quality of life of postmenopausal women in the ATAC ("Arimidex," tamoxifen alone or in combination) trial after completion of 5 years' adjuvant treatment for early stage breast cancer. *Breast Cancer Res Treat* 2006;100:273-284.
63. Whelan TJ, Pritchard KI. Managing patients on endocrine therapy: focus on quality-of-life issues. *Clin Cancer Res* 2006;12:1056s-1060s.
64. Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. *J Clin Oncol* 2005;23:6931-6940.
65. Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. *Maturitas* 2010;67:233-238.
66. Kirchheiner K, Fidarova E, Nout RA, et al. Radiation-induced morphological changes in the vagina. *Strahlenther Onkol* 2012;188:1010-1017.
67. Fisher BK. Normal anatomy of the vulva. In: Fisher BK, Margesson LJ, editors. *Genital Skin Disorders: Diagnosis and Treatment*. St Louis, MO: Mosby; 1998. pp. 99-107.
68. Sobel JD, Reichman O, Misra D, Yoo W. Prognosis and treatment of desquamative inflammatory vaginitis. *Obstet Gynecol* 2011;117:850-855.
69. Capobianco G, Donolo E, Borghero G, Dessole F, Cherchi PL, Dessole S. Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. *Arch Gynecol Obstet* 2012;285:397-403.
70. Mercier J, Morin M, Zaki D, et al. Pelvic floor muscle training as a treatment for genitourinary syndrome of menopause: a single-arm feasibility study. *Maturitas* 2019;125:57-62.
71. Lee YK, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. *Obstet Gynecol* 2011; 117:922-927.
72. Mitchell CM0, Reed SD, Diem S, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. *JAMA Intern Med* 2018;178:681-690.
73. Jozkowski KN, Herbenick D, Schick V, Reece M, Sanders SA, Fortenberry JD. Women's perceptions about lubricant use and vaginal wetness during sexual activities. *J Sex Med* 2013;10:484-492.
74. Pitsouni E, Grigoriadis T, Douskos A, Kyriakidou M, Falagas M, Athanasiou S. Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: a systematic review and meta-analysis of randomized controlled trials. *Eur J Obstet Gynecol Reprod Biol* 2018;229:45-56.
75. Hickey M, Marino JL, Braat S, Wong S. A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer. *Breast Cancer Res Treat* 2016; 158:79-90.
76. Dezzutti CS, Brown ER, Moncla B, et al. Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity. *PLoS One* 2012;7:e48328.

77. Wilkinson EM, Laniewski P, Herbst-Kralovetz MM, Brotman RM. Personal and clinical vaginal lubricants: impact on local vaginal micro-environment and implications for epithelial cell host response and barrier function. *J Infect Dis* 2019;220:2009-2018.
78. Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? *Climacteric* 2016;19:151-161.
79. Brown JM, Hess KL, Brown S, Murphy C, Waldman AL, Hezareh M. Intravaginal practices and risk of bacterial vaginosis and candidiasis infection among a cohort of women in the United States. *Obstet Gynecol* 2013;121:773-780.
80. Chen J, Geng L, Song X, Li H, Giordan Liao Q. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. *J Sex Med* 2013;10:1575-1584.
81. Grimaldi EP, Restaino S, Inglese S, et al. Role of high molecular weight hyaluronic acid in postmenopausal vaginal discomfort. *Minerv Ginecol* 2012;64:321-329.
82. Ekin M, Yasar L, Savan K, et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. *Arch Gynecol Obstet* 2011;283: 539-543.
83. LeDonne M, Caruso C, Mancuso A, et al. The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause. *Arch Gynecol Obstet* 2011;283:1319-1323.
84. Reed SD, Newton KM, LaCroix AZ, Grothaus LC, Grieco VS, Erlich K. Vaginal, endometrial, and reproductive hormone findings: randomized placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. *Menopause* 2008;15:51-58.
85. Santen RJ, Pinkerton JV, Liu JH, et al. Workshop on normal reference ranges for estradiol in postmenopausal women, September 2019, Chicago, Illinois. *Menopause* 2020;27:614-624.
86. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. *Menopause* 2017;24:728-753.
87. Mitchell CM, Srinivasan S, Plantinga A, et al. Associations between improvement in genitourinary symptoms of menopause and changes in the vaginal ecosystem. *Menopause* 2018;25:500-507.
88. Lindau ST, Dude A, Gavrilova N, Hoffmann JN, Schumm LP, McClintock MK. Prevalence and correlates of vaginal estrogenization in postmenopausal women in the United States. *Menopause* 2017;24:536-545.
89. Estrace [package insert]. Madison, NJ: Allergan; 2018.
90. Premarin [package insert]. Philadelphia, PA: Pfizer; 2015.
91. Estragyn [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma; 2016.
92. Imvexxy [package insert]. Boca Raton, FL: TherapeuticsMD; 2019.
93. Vagifem [package insert]. Plainsboro, NJ: Novo Nordisk; 2019.
94. Yuvaferm [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals; 2016.
95. Intrarosa [package insert]. Waltham, MA: Amag Pharmaceuticals; 2018.
96. Estring [product insert]. New York: Pfizer; 2015.
97. Osphena [package insert]. Florham Park, NJ: Shionogi; 2019.
98. Bygdeman M, Swahn ML. Replens versus dienestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. *Maturitas* 1996;23:259-263.
99. Ayton RA, Darling GM, Murkies AL, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. *Br J Obstet Gynaecol* 1996;103:351-358.
100. Nachtigall L. Clinical trial of the estradiol vaginal ring in the U.S. *Maturitas* 1995;22:S43-S47.
101. Manonai J, Theppisai U, Suthutvoravut S, Udomsubpayakul U, Chitacharoen A. The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study. *J Obstet Gynaecol Res* 2001;27:255-260.
102. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. *Menopause* 2000;7:156-161.
103. Barentsen R, van de Weijer PH, Schram JH. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. *Eur J Obstet Gynecol Reprod Biol* 1997;7:73-80.
104. Casper F, Petri E. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. *Int Urogynecol J Pelvic Floor Dysfunct* 1999;10:171-176.
105. Henriksson L, Stjernquist M, Boquist L, Alander U, Selinus I. A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. *Am J Obstet Gynecol* 1994;171:624-632.
106. Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestrial vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. *BJOG* 2000;107:1029-1034.
107. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. *Climacteric* 2005;8:83-92.
108. Eriksen PS, Rasmussen H. Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. *Eur J Obstet Gynecol Reprod Biol* 1992;44:137-144.
109. Dugal R, Hesla K, Sordal T, Aase KH, Lilleeidet O, Wickström E. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. *Acta Obstet Gynecol Scand* 2000;79:293-297.
110. Foidart JM, Vervliet J, Buytaert P. Efficacy of sustained-release vaginal oestrial in alleviating urogenital and systemic climacteric complaints. *Maturitas* 1991;13:99-107.
111. Garcia LE. Efficiency of vaginal ovules of estriol for treatment of symptoms of menopause. *Investigacion Medica Internacional* 1993;19: 159-165.
112. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. *Cochrane Database Syst Rev* 2016;CD001500.
113. Rahn DD, Carberry C, Sanses TV, et al; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. *Obstet Gynecol* 2014;124: 1147-1156.
114. Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. *Cochrane Database Syst Rev* 2012;10:CD001405.
115. Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T; HERS Research Group. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. *Obstet Gynecol* 2001;97:116-120.
116. Nelken RS, Ozel BZ, Leegant AR, Felix JC, Mishell DR Jr. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. *Menopause* 2011;18:962-966.
117. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women: a review. *JAMA* 2017;318:1592-1604.
118. Suskind AM, Saigal CS, Hanley JM, Lai J, Setodji CM, Clemens JQ; Urologic Diseases of America Project. Incidence and management of uncomplicated recurrent urinary tract infections in a national sample of women in the United States. *Urology* 2016;90:50-55.
119. Ferrante KL, Wasenda EJ, Jung CE, Adams-Piper ER, Lukacz ES. Vaginal estrogen for the prevention of recurrent urinary tract infection in postmenopausal women: a randomized clinical trial. *Female Pelvic Med Reconstr Surg* 2019; [published online ahead of print June 19, 2019].
120. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. *N Engl J Med* 1993;329:753-757.
121. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infection in postmenopausal women. *Am J Obstet Gynecol* 1999;180:1072-1079.
122. Dessie SG, Armstrong K, Modest AM, Hacker MR, Hota LS. Effect of vaginal estrogen on pessary use. *Int Urogynecol J* 2016;27:1423-1429.
123. Lee JS, Ettinger B, Stanczyk FZ, et al. Comparison of methods to measure low serum estradiol levels in postmenopausal women. *J Clin Endocrinol Metab* 2006;91:3791-3797.
124. Schmidt G, Andersson SB, Nordle O, Johansson CJ, Gunnarsson PO. Release of 17-beta-estradiol from a vaginal ring in postmenopausal women: pharmacokinetic evaluation. *Gynecol Obstet Invest* 1994;38:253-260.
125. Naessen T, Rodriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women. *Am J Obstet Gynecol* 2002;186:944-947.
126. Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. *Menopause* 2002; 9:179-187.



127. Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. *Obstet Gynecol* 2002; 99:556-562.
128. Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. *Climacteric* 2010;13:219-227.
129. Stanczyk FZ, Lee JS, Santen RJ. Standardization of steroid hormone assays: why, how, and when? *Cancer Epidemiol Biomarkers Prev* 2007;16:1713-1719.
130. Luisi M, Franchi F, Kicovic PM. A group-comparative study of effects of Ovestin cream versus premarin cream in post-menopausal women with vaginal atrophy. *Maturitas* 1980;2:311-319.
131. Martin PL, Yen SS, Burnier AM, Hermann H. Systemic absorption and sustained effects of vaginal estrogen creams. *JAMA* 1979;242:2699-2700.
132. Handa VL, Bachus KE, Johnston WW, Robboy SJ, Hammond CB. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. *Obstet Gynecol* 1994;84: 215-218.
133. Fischer G, Bradford J. Vulvovaginal candidiasis in postmenopausal women: the role of hormone replacement therapy. *J Low Genit Tract Dis* 2011;15:263-267.
134. Dennerstein GJ, Ellis DH. Oestrogen, glycogen and vaginal candidiasis. *Aust N Z J Obstet Gynaecol* 2001;41:326-328.
135. Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. *Menopause* 2018;25:11-20.
136. Constantine GD, Graham S, Lapane K, et al. Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review. *Menopause* 2019;26:800-807.
137. Crandall CJ, Diamant A, Santoro N. Safety of vaginal estrogens: a systematic review. *Menopause* 2020;27:339-360.
138. Bhupathiraju N, Grodstein F, Stampfer MJ, et al. Vaginal estrogen use and chronic disease risk in the Nurses' Health Study. *Menopause* 2018;26:603-610.
139. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. *BMJ* 2019;364: k4810. Erratum in: *BMJ* 2019;364:1162.
140. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. *Lancet* 2019;394:1159-1168.
141. Femring [package insert]. Rockaway, NJ: Warner Chilcott; 2009.
142. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. *Obstet Gynecol* 2008;112:1053-1060.
143. Pickar JH, Amadio JM, Bernick BA, Mirkin S. Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule. *Climacteric* 2016;19:181-187.
144. Simon JA, Archer DF, Constantine GD, et al. A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: efficacy and pharmacokinetic data review. *Maturitas* 2017;99:51-58.
145. Constantine GD, Simon JA, Pickar JH, et al. Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data. *Curr Med Res Opin* 2018;34:2131-2136.
146. Labrie F, Archer DF, Koltun W, et al; VVA Prasterone Research Group. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. *Menopause* 2016;23:243-256.
147. Portman DJ, Labrie F, Archer DF, et al; other participants of VVA Prasterone Group. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. *Menopause* 2015;22:1289-1295.
148. Pinkerton JV, Thomas S. Use of SERMs for treatment in postmenopausal women. *J Steroid Biochem Mol Biol* 2014;142:142-154.
149. Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. *Menopause* 2013;20:623-630.
150. Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. *Menopause* 2010;17:480-486.
151. Archer DF, Goldstein SR, Simon JA, et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. *Menopause* 2019;26:611-621.
152. Simon JA, Lin VH, Radovich C, Bachmann GA; The Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. *Menopause* 2013;20:418-427.
153. Schiavi MC, Di Pinto A, Sciuga V, et al. Prevention of recurrent lower urinary tract infections in postmenopausal women with genitourinary syndrome: outcome after 6 months of treatment with ospemifene. *Gynecol Endocrinol* 2018;34:140-143.
154. Wurz GT, Soe LH, Degregorio MW. Ospemifene, vulvovaginal atrophy, and breast cancer. *Maturitas* 2013;74:220-225.
155. Eigeliene N, Kangas L, Hellmer C, Kauko T, Erkkola R, Härkönen P. Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo. *Menopause* 2016;23:719-730.
156. Cai B, Simon J, Villa P, et al. Lower incidence and recurrence of breast cancer in ospemifene treated patients with vulvovaginal atrophy (VVA). *Maturitas*. In press.
157. Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. *Obstet Gynecol* 2010;116:876-883.
158. Johnston SL, Farrell SA, Bouchard C, et al; SOGC Joint Committee-Clinical Practice Gynaecology and Urogynaecology. The detection and management of vaginal atrophy. *J Obstet Gynaecol Can* 2004;26: 503-515.
159. American College of Obstetricians and Gynecologists Women's Health Care Physicians. Genitourinary tract changes. *Obstet Gynecol* 2004;104:56S-61S.
160. Chi CC, Kirtschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F. Topical interventions for genital lichen sclerosis. *Cochrane Database Syst Rev* 2011;7:CD008240.
161. Burrows LJ, Goldstein AT. The treatment of vestibulodynia with topical estradiol and testosterone. *Sex Med* 2013;1:30-33.
162. Witherby S, Johnson J, Demers L, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. *Oncologist* 2011;16:424-431.
163. Melisko ME, Goldman ME, Hwang J, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. *JAMA Oncol* 2017;3:313-319.
164. Simon JA, Goldstein I, Kim NN, et al. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. *Menopause* 2018;25:837-847.
165. US Food and Drug Administration. FDA warns against use of energy-based devices to perform vaginal "rejuvenation" or vaginal cosmetic procedures: FDA Safety Communication. July 30, 2018.
166. Ong MW, Bashir SJ. Fractional laser resurfacing for acne scars: a review. *Br J Dermatol* 2012;166:1160-1169.
167. Tierney EP, Hanke CW. Fractionated carbon dioxide laser treatment of photoaging: prospective study in 45 patients and review of the literature. *Dermatol Surg* 2011;37:1279-1290.
168. Tierney EP, Hanke CW. Ablative fractionated CO2 laser resurfacing for the neck: prospective study and review of the literature. *J Drugs Dermatol* 2009;8:723-731.
169. Peterson JD, Goldman MP. Rejuvenation of the aging chest: a review and our experience. *Dermatol Surg* 2011;37:555-571.
170. Athanasiou S, Pitsouni E, Grigoriadis T, et al. Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results. *Menopause* 2019;26:248-255.
171. Becorpi A, Campisciano G, Zanotta N, et al. Fractional CO2 laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects. *Lasers Med Sci* 2018;33:1047-1054.
172. Biglia N, Bounous VE, Sgro LG, D'Alonzo M, Pecchio S, Nappi RE. Genitourinary syndrome of menopause in breast cancer survivors: are we facing new and safe hopes? *Clin Breast Cancer* 2015;15:413-420.
173. Filippini M, Luvero D, Salvatore S, et al. Efficacy of fractional CO2 laser treatment in postmenopausal women with genitourinary syndrome: a multicenter study. *Menopause* 2020;27:43-49.



174. Pagano T, De Rosa P, Vallone R, et al. Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. *Menopause* 2018;25:657-662.
175. Perino A, Calligaro A, Forlani F, et al. Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser. *Maturitas* 2015;80:296-301.
176. Pieralli A, Fallani MG, Becorpi A, et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. *Arch Gynecol Obstet* 2016;294:841-846.
177. Sokol ER, Karram MM. Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes. *Menopause* 2017;24:810-814.
178. Zerbinati N, Serati M, Origoni M, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. *Lasers Med Sci* 2015;30:429-436.
179. Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. *Menopause* 2018;25:21-28.
180. Paraiso MFR, Ferrando CA, Sokol ER, et al. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: the VeLVET Trial. *Menopause* 2020;27:50-56.
181. Politano CA, Costa-Paiva L, Aguiar LB, Machado HC, Baccaro LF. Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial. *Menopause* 2019;26:833-840.
182. Gaspar A, Brandi H, Gomez V, Luque D. Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. *Lasers Surg Med* 2017;49:160-168.
183. Gordon C, Gonzales S, Krychman ML. Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy. *Menopause* 2019;26:423-427.
184. The American College of Obstetricians and Gynecologists. Fractional laser treatment of vulvovaginal atrophy and US Food and Drug Administration Clearance: position statement. May 2016. Reaffirmed July 2018.
185. Alshiek J, Garcia B, Minassian V, et al. Vaginal energy-based devices [published online ahead of print April 22, 2020]. *Female Pelvic Med Reconstr Surg*.
186. Shobeiri SA, Kerkhof M, Minassian VA, Bazi T; IUGA Research and Development Committee. IUGA committee opinion: laser-based vaginal devices for treatment of stress urinary incontinence, genitourinary syndrome of menopause, and vaginal laxity. *Int Urogynecol J* 2019;30:371-376.
187. Preti M, Vieira-Baptista P, Digesu GA, et al. The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: an ICS/ISSVD best practice consensus document. *Neurourol Urodyn* 2019;38:1009-1023.
188. Moreno AC, Sikka SK, Thacker HL. Genitourinary syndrome of menopause in breast cancer survivors: treatments are available. *Cleve Clin J Med* 2018;85:760-766 Erratum in: *Cleve Clin J Med* 2018; 85:860.
189. Phua C, Baber R. The management of menopausal symptoms in women following breast cancer: an overview. *Drugs Aging* 2018;35: 699-705.
190. Streicher L, Simon JA. Sexual function post-breast cancer. *Cancer Treat Res* 2018;173:167-189.
191. Goetsch M, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled clinical trial. *J Clin Oncol* 2015;33:3394-3400.
192. Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. *Menopause* 2020;27:361-370.
193. Pavlović RT, Janković SM, Milovanović JR, et al. The safety of local hormonal treatment for vulvovaginal atrophy in women with estrogen receptor-positive breast cancer who are on adjuvant aromatase inhibitor therapy: meta-analysis. *Clin Breast Cancer* 2019;19:e731-e740.
194. Martel C, Labrie F, Archer DF, et al; other participating members of the Prasterone Clinical Research Group. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5 mg intravaginal prasterone for 12 weeks. *J Steroid Biochem Mol Biol* 2016;159:142-153.
195. Quick AM, Zvinovski F, Hudson C, et al. Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors. *Support Care Cancer* 2020;28:3669-3677.
196. Arêas F, Valadares ALR, Conde DM, Costa-Paiva L. The effect of vaginal erbium laser treatment on sexual function and vaginal health in women with a history of breast cancer and symptoms of the genitourinary syndrome of menopause: a prospective study. *Menopause* 2019;26:1052-1058.
197. Flint R, Cardozo L, Grigoriadis T, Rantell A, Pitsouni E, Athanasiou S. Rationale and design for fractional microablative CO2 laser versus photothermal non-ablative erbium:YAG laser for the management of genitourinary syndrome of menopause: a non-inferiority, single-blind randomized controlled trial. *Climacteric* 2019;22:307-311.

The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society has been designated a CME activity for all NAMS members. NAMS members should log-in to the NAMS website [www.menopause.org](http://www.menopause.org) and then select Online CME in the Member Center. CME credit will be available from September 1, 2020, to September 1, 2021.